EPO tecting the endothelium

T. E. Peterson, Zvonimir S Katusic

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Erythropoietin is a 30.4 kDa protein that is produced and secreted from the kidney in response to anemia and hypobaric hypoxia. Binding of EPO to its receptor (EPO-R) on bone marrow-derived erythroid progenitor cells results in the stimulation of red blood cell production. Evidence is accumulating however, that the biological effects of recombinant EPO therapy extend beyond the stimulation of erythropoiesis. The discovery that the EPO-R is expressed on vascular endothelial cells suggests that the vasculature may be a biological target of EPO. Indeed, several studies have now demonstrated that the protective effect of EPO administration involves the activation of the protein kinase B/Akt pathway which can protect cells from apoptosis. Future work is likely to provide further insight into the mechanisms by which EPO protects vascular endothelial cells from injury and give us a better understanding of the pharmacological doses that are required to achieve this protection.

Original languageEnglish (US)
Pages (from-to)823-825
Number of pages3
JournalBritish Journal of Pharmacology
Volume150
Issue number7
DOIs
StatePublished - Apr 2007

Fingerprint

Endothelium
Endothelial Cells
Proto-Oncogene Proteins c-akt
Erythroid Precursor Cells
Erythropoiesis
Erythropoietin
Anemia
Erythrocytes
Bone Marrow
Pharmacology
Apoptosis
Kidney
Wounds and Injuries
Proteins
Therapeutics
Hypoxia

ASJC Scopus subject areas

  • Pharmacology

Cite this

EPO tecting the endothelium. / Peterson, T. E.; Katusic, Zvonimir S.

In: British Journal of Pharmacology, Vol. 150, No. 7, 04.2007, p. 823-825.

Research output: Contribution to journalArticle

Peterson, T. E. ; Katusic, Zvonimir S. / EPO tecting the endothelium. In: British Journal of Pharmacology. 2007 ; Vol. 150, No. 7. pp. 823-825.
@article{44f841877db64d99b821cb301208a4b0,
title = "EPO tecting the endothelium",
abstract = "Erythropoietin is a 30.4 kDa protein that is produced and secreted from the kidney in response to anemia and hypobaric hypoxia. Binding of EPO to its receptor (EPO-R) on bone marrow-derived erythroid progenitor cells results in the stimulation of red blood cell production. Evidence is accumulating however, that the biological effects of recombinant EPO therapy extend beyond the stimulation of erythropoiesis. The discovery that the EPO-R is expressed on vascular endothelial cells suggests that the vasculature may be a biological target of EPO. Indeed, several studies have now demonstrated that the protective effect of EPO administration involves the activation of the protein kinase B/Akt pathway which can protect cells from apoptosis. Future work is likely to provide further insight into the mechanisms by which EPO protects vascular endothelial cells from injury and give us a better understanding of the pharmacological doses that are required to achieve this protection.",
author = "Peterson, {T. E.} and Katusic, {Zvonimir S}",
year = "2007",
month = "4",
doi = "10.1038/sj.bjp.0707162",
language = "English (US)",
volume = "150",
pages = "823--825",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - EPO tecting the endothelium

AU - Peterson, T. E.

AU - Katusic, Zvonimir S

PY - 2007/4

Y1 - 2007/4

N2 - Erythropoietin is a 30.4 kDa protein that is produced and secreted from the kidney in response to anemia and hypobaric hypoxia. Binding of EPO to its receptor (EPO-R) on bone marrow-derived erythroid progenitor cells results in the stimulation of red blood cell production. Evidence is accumulating however, that the biological effects of recombinant EPO therapy extend beyond the stimulation of erythropoiesis. The discovery that the EPO-R is expressed on vascular endothelial cells suggests that the vasculature may be a biological target of EPO. Indeed, several studies have now demonstrated that the protective effect of EPO administration involves the activation of the protein kinase B/Akt pathway which can protect cells from apoptosis. Future work is likely to provide further insight into the mechanisms by which EPO protects vascular endothelial cells from injury and give us a better understanding of the pharmacological doses that are required to achieve this protection.

AB - Erythropoietin is a 30.4 kDa protein that is produced and secreted from the kidney in response to anemia and hypobaric hypoxia. Binding of EPO to its receptor (EPO-R) on bone marrow-derived erythroid progenitor cells results in the stimulation of red blood cell production. Evidence is accumulating however, that the biological effects of recombinant EPO therapy extend beyond the stimulation of erythropoiesis. The discovery that the EPO-R is expressed on vascular endothelial cells suggests that the vasculature may be a biological target of EPO. Indeed, several studies have now demonstrated that the protective effect of EPO administration involves the activation of the protein kinase B/Akt pathway which can protect cells from apoptosis. Future work is likely to provide further insight into the mechanisms by which EPO protects vascular endothelial cells from injury and give us a better understanding of the pharmacological doses that are required to achieve this protection.

UR - http://www.scopus.com/inward/record.url?scp=34047202482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047202482&partnerID=8YFLogxK

U2 - 10.1038/sj.bjp.0707162

DO - 10.1038/sj.bjp.0707162

M3 - Article

C2 - 17351666

AN - SCOPUS:34047202482

VL - 150

SP - 823

EP - 825

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 7

ER -